Timothy P. Coughlin's most recent trade in Adc Therapeutics SA was a trade of 80,000 Stock Options (Right to Buy) done . Disclosure was reported to the exchange on June 3, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adc Therapeutics SA | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 80,000 | 80,000 | - | - | Stock Options (Right to Buy) | |
| Adc Therapeutics SA | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 40,000 | 40,000 | - | 0 | Common Shares | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 6,500 | 55,500 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy Coughlin P. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 07 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 30 May 2024 | 50,000 | 56,000 (0%) | 0% | 1.8 | 87,500 | Common Stock |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 24,000 | 24,000 | - | - | Stock Option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 49,000 (0%) | 0% | 0 | Common Stock | |
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | ||
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2023 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 17 May 2023 | 6,000 | 6,000 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 17 May 2023 | 6,000 | 0 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,000 | 6,000 (0%) | 0% | - | Common stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Apr 2023 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 09 Jun 2022 | 11,893 | 11,893 | - | - | Stock Option (Right to Buy) | ||
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 09 Jun 2022 | 8,650 | 9,892 (0%) | 0% | 0 | Common Stock | ||
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 03 Jun 2022 | 1,439 | 57,632 (0%) | 0% | 22.8 | 32,824 | Common Stock | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 38,000 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 6,000 | 6,000 | - | - | Restricted Stock Units | |
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 02 Jun 2021 | 4,334 | 4,334 | - | - | Stock Option (Right to Buy) | ||
| Fate Therapeutics Inc | Timothy P. Coughlin | Director | 02 Jun 2021 | 2,681 | 59,071 (0%) | 0% | 0 | Common Stock | ||
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,000 | 35,000 (0%) | 0% | 0 | Common Stock | |
| Atyr Pharma Inc | Timothy P. Coughlin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2021 | 1,428 | 1,428 | - | - | Stock Option (right to buy) |